Notice of Results and Investor Presentation

10 April 2025

Futura Medical plc

("Futura" or the "Company")

Notice of Results and Investor Presentation

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, will announce its results for the year ended 31 December 2024 on Tuesday 15 April 2025.

The Company will be hosting a webinar for retail investors via the Investor Meet Company platform on 15 April 2025, at 10:00am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9:00am BST the day before, or at any time during the live presentation.

Investors can register for the presentation via the following link: https://www.investormeetcompany.com/futura-medical-plc/register-investor

In addition, management will be hosting a webinar for analysts on 15 April 2025 at 11:00am BST. If you would like to register, please contact [email protected].

Contacts:

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.

Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.